HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update
* Full-Year 2022 net revenue of KRW 110 billion, up 8% over 2021 reaching a record high * Strong R&D momentum to continue with batoclimab entering multiple pivotal studies with the first Phase 3 data readout inChina expected in 2023 * Top-line data from tanfanercept's Phase 3 dry eye study e...
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update
* Financial results for Q3 2022 ended with revenue of KRW 29.6 billion with continued growth in the pharmaceutical division driven by product portfolio expansion and strong sales in major products * R&D expenses for the quarter increased by 63%, reflecting the preparation of a Phase 3 study i...
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab
* Harbour BioMed, HanAll's licensed partner in China, signed a sublicense agreement with CSPC NBP Pharmaceutical for batoclimab, an FcRn compound originally discovered and developed by HanAll Biopharma * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China, ...
HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner
* Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402) * In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL cholesterol level * Batoclimab (form...
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update
* Financial performance for Q2 2022 records revenues of KRW 26.2 billion, a 12% growth from the same period last year, driven by strong sales performance from the pharmaceutical division * Operating income turned to profit compared to the last quarter, while investment to R&D continued in t...
HanAll Biopharma Reports First Quarter 2022 Results and Provides Business Update
* HanAll will expand R&D investments to advance its late-stage pipeline assets SEOUL, South Korea, April 28, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), a global biopharma company committed to deliver innovative and impactful therapeutics to address severe unmet medical needs, tod...
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative
* HanAll Biopharma and Daewoong Pharmaceutical invest in the broad potential of Turn Biotechnologies * Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases SEOUL, South Korea ,April 12, 2022 /PRNewswire/ -- HanAll...
HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer
SEOUL, South Korea, Feb. 21, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) announced today the appointment ofAlmira Chabi, M.D. as Chief Medical Officer and Chief Development Officer at HanAll Pharmaceutical International (HPI), a U.S. entity wholly owned by HanAll Biopharma, to strengt...
HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update
* 2021 sales of KRW 101.6 billion for a 15% increase from 2020 * 2021 operating profit of KRW 10.1 billion grew by 70% from 2020 * Increasing milestone payments and revenues from R&D activities are reinvested into new R&D programs SEOUL, South Korea, Jan. 20, 2022 /PRNewswire/ -- [Busines...
HanAll Biopharma Reports Third Quarter 2021 Results
* Q3'21 sales of KRW 25.5 billion increased 15% from the same period last year * Q3'21 operating profit of KRW 2.2 billion grew by 120% compared to Q3'20 * Nine months sales of KRW 76.7 billion and operating profit of KRW 9.2 billion rose by 15% and 67% YoY, repectively SEOUL, South Korea, Oct...
Daewoong Pharmaceutical and Hanall Biopharma Invest $1M USD in Alloplex Biotherapeutics
SEOUL, South Korea, Aug. 19, 2021 /PRNewswire/ -- Daewoong Pharmaceutical and
Hanall Biopharma ofSouth Korea are expanding their global open collaboration
initiative by investing in Alloplex Biotherapeutics, an emergingBoston-based
biotechnology company.
HanAll Biopharma Reports Second Quarter 2021 Results
* Q2'21 sales of KRW 23.4 billion increased 4% from the same period last year * Q2'21 operating profit of KRW 1.6 billion fell slightly by 3% compared to Q2'20 * H1'21 sales of KRW 51.2 billion and operating profit of 6.3 billion grew by 15% and 56% YoY [Business Performance and Financial St...
HanAll Biopharma Reports First Quarter 2021 Financial Results
* Q1'21 sales of KRW 27.8 billion increased 26% compared to Q1'20 * Q1'21 operating profit of KRW 5.4 billion increased 80% compared to Q1'20 * Q1'21 operating margin of 19%, up from 14% in Q1'20 * Better-than-expected sales and operating profit are largely due to an increase of R&D revenue...
HanAll Biopharma and Harbour BioMed Sign Collaboration and License Agreement to Develop Two Novel Biologic Therapies in Greater China
SEOUL, South Korea, SHANGHAI and CAMBRIDGE, Massachusetts, Sept. 12, 2017 /PRNewswire/ -- HanAll Biopharma Co., Ltd. (009420.KS) and Harbour BioMed announced today that they have entered into a strategic collaboration and license agreement to develop, manufacture and commercialize inGreater China...
